NasdaqGM - Delayed Quote • USD
ADMA Biologics, Inc. (ADMA)
At close: April 23 at 4:00 PM EDT
After hours: April 23 at 7:45 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 4 | 4 | 4 | 4 |
| Avg. Estimate | 0.05 | 0.07 | 0.3 | 0.5 |
| Low Estimate | 0.05 | 0.06 | 0.28 | 0.48 |
| High Estimate | 0.07 | 0.08 | 0.32 | 0.51 |
| Year Ago EPS | -0.03 | -0.03 | -0.13 | 0.3 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 4 | 4 | 4 | 4 |
| Avg. Estimate | 77.27M | 81.27M | 333.87M | 389.87M |
| Low Estimate | 76M | 78.4M | 331.9M | 383.5M |
| High Estimate | 79.7M | 83M | 337M | 395.5M |
| Year Ago Sales | 56.91M | 60.12M | 258.21M | 333.87M |
| Sales Growth (year/est) | 35.80% | 35.20% | 29.30% | 16.80% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.04 | -0.02 | -0.01 | 0.02 |
| EPS Actual | -0.03 | -0.03 | 0.01 | -0.08 |
| Difference | 0.01 | -0.01 | 0.02 | -0.1 |
| Surprise % | 25.00% | -50.00% | 200.00% | -500.00% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 0.05 | 0.07 | 0.3 | 0.5 |
| 7 Days Ago | 0.05 | 0.07 | 0.3 | 0.5 |
| 30 Days Ago | 0.05 | 0.07 | 0.3 | 0.5 |
| 60 Days Ago | 0.04 | 0.05 | 0.23 | 0.4 |
| 90 Days Ago | 0.04 | 0.05 | 0.23 | 0.4 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | ADMA | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 266.70% | -- | -- | 0.40% |
| Next Qtr. | 333.30% | -- | -- | 9.90% |
| Current Year | 330.80% | -- | -- | 4.30% |
| Next Year | 66.70% | -- | -- | 13.40% |
| Next 5 Years (per annum) | -- | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Buy to Buy | 3/26/2024 |
| Maintains | Mizuho: Buy to Buy | 3/1/2024 |
| Maintains | Cantor Fitzgerald: Overweight to Overweight | 2/29/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 2/29/2024 |
| Maintains | Mizuho: Buy to Buy | 1/22/2024 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 1/9/2024 |
Related Tickers
ANNX Annexon, Inc.
4.4400
-2.31%
LGND Ligand Pharmaceuticals Incorporated
69.89
+1.98%
EYEN Eyenovia, Inc.
0.5426
+5.05%
ALDX Aldeyra Therapeutics, Inc.
3.9100
-0.51%
PBYI Puma Biotechnology, Inc.
5.13
-0.77%
ENTX Entera Bio Ltd.
2.2200
+8.29%
VNDA Vanda Pharmaceuticals Inc.
4.6300
-3.54%
CADL Candel Therapeutics, Inc.
5.91
+6.68%
ANVS Annovis Bio, Inc.
11.88
+3.39%
FGEN FibroGen, Inc.
1.0700
-6.14%